Nature Reviews: Drug Discovery 2008-12-01

End of the line for cannabinoid receptor 1 as an anti-obesity target?

Dan Jones

Index: Nat. Rev. Drug Discov. 7(12) , 961-2, (2008)

Full Text: HTML

Abstract

A wave of terminations of development programmes for cannabinoid receptor 1 blockers for obesity indicates the demise of a drug class that was once anticipated to yield blockbusters. Nevertheless, lessons learned might help salvage something for future such approaches.

Related Compounds

  • (S)-fenfluramine h...

Related Articles:

Pulmonary hypertension and the serotonin hypothesis: where are we now?

2007-09-01

[Int. J. Clin. Pract. Suppl. (156) , 27-31, (2007)]

O2 reduction by a functional heme/nonheme bis-iron NOR model complex.

2009-06-30

[Proc. Natl. Acad. Sci. U. S. A. 106(26) , 10528-33, (2009)]

Ribonuclease S redux.

2011-01-21

[Chem. Commun. (Camb.) 47(3) , 973-5, (2011)]

A novel procedure for assessing the effects of drugs on satiation in baboons: effects of memantine and dexfenfluramine.

2008-09-01

[Psychopharmacology 199(4) , 583-92, (2008)]

Consumption of palatable food decreases the anorectic effects of serotonergic, but not dopaminergic drugs in baboons

2011-07-06

[Physiol. Behav. 103(5) , 493-500, (2011)]

More Articles...